Designing the Future of Longevity
by Wasu Mekniran
Scaling Digital Health for Prevention
Incentive Alignment and Sustainable Financing in Switzerland
Where Prevention Stalls
Reach
Expand access through digital channels
Retain
Sustain participation through behavioral design
Report
Measure outcomes and generate evidence
Reimburse
Close financing loop through value-based contracts
Prevention — the part of healthcare financing where costs are immediate, benefits are invisible, and adoption fails unless incentives are redesigned.
"Miss one, you stall... Align all four, and prevention scales."
Research & Findings
Global Investment Trends Analysis
Where are global stakeholders putting their chips?
Methodology & Sample
Key Finding
Investment Allocation Priorities
Present Effort
UNMET DEMAND
Digital Health Technology Analysis
How can DHTs and financing mechanisms address incentive failures in prevention?
Methodology & Sample
Value Propositions Match Revenue Model
Successful prevention ventures match technology capabilities with appropriate financing models
DHT Impact → Financing Model Match
Swiss Market Viability Assessment
Can prevention ventures generate sustainable cash flow in Switzerland?
Health System Evaluation & Discounted Cashflow Modeling
Valuation Comparison (CHF Million)
How It Works
Our research leverages data integration that connects signals across science, finance, and health policy to identify overlooked investable assets.
- OECD, World Bank & WHO – macroeconomic and population metrics
- PitchBook & Crunchbase – venture funding intelligence
- PubMed – scientific and clinical studies
- FDA Database – regulatory approvals
- IP Databases (USPTO, Espacenet) – early technology signals
- Hospital Statistics – national healthcare and cost data
- Bloomberg Terminal – discounted cash flow modeling inputs
- HTA Databases (Swiss HTA, NICE) – reimbursement benchmarks
Our Work
Explore our latest research in digital health and longevity investment.
Wasu Mekniran, Tobias Kowatsch
Biomedical Engineering Conference - Portugal
Wasu Mekniran
Key Findings
- DHT shows 40% faster market differentiation but 65% smaller average funding rounds
- BioTech maintains revenue model advantages despite 67% higher failure rates
- Four strategic positioning quadrants identified for competitive advantage
Wasu Mekniran, Lukasz Paciorkowski, Iwona Cymerman, Rafal Pawlowski
4th Swiss-Polish Economic and Technology Forum
Wasu Mekniran, Mia Jovanova, Tobias Kowatsch
Swiss Society of Endocrinology and Diabetes 2024
Wasu Mekniran, Jan-Niklas Kramer, Tobias Kowatsch
Biomedical Engineering Conference - Italy
Key Findings
- Swiss healthcare system focuses on sick care rather than preventive care
- DHTs show highest value for NCDs and stigmatized conditions with care shortages
- Health insurers can pursue three strategic approaches: cost leadership, contract innovation, or healthcare provider role
Wasu Mekniran, Tobias Kowatsch
Biomedical Engineering Conference - Portugal
Key Findings
- Analysis of $1.73 billion in funding across 10 digital health companies
- 9 out of 10 companies target corporate customers rather than individual patients
- Companies scale by developing platforms for wide user ranges vs. specific demographics
- Recommendations for prioritizing employer partnerships and aligning patient-payer incentives
Wasu Mekniran, Odile-Florence Giger, Elgar Fleisch, Tobias Kowatsch, Mia Jovanova
SWU Biomedical Engineering Dept.
Wasu Mekniran, Research Team
NUS Healthy Longevity Academy
Key Findings
- Research done
- Results under review
- Expected publication Q3 2025
Wasu Mekniran, Collaborators
ETH AI Center
Key Findings
- Data collection ongoing
- Model development in progress
- Expected submission Q4 2025
About me.
Our Missions
Identify and quantify stakeholder incentives, test business models that link early detection and prevention with long-term gains in healthy life years.
👉 "Where is the overlap between payer affordability, provider workflow, patient willingness, and investor ROI — and how can digital prevention ventures position themselves inside that overlap?"
Align Incentives
Reimagining healthy longevity as a systems challenge, where health data, economic planning, and family engagement converge to sustain care across the lifespan.
Make Longevity an investable asset
Finding mispriced prevention ventures and separate hype from true cashflow with evidence. Transfer analytical signals across equities, bonds, REITs, and tokenized assets.
Wasu Mekniran
I don't see my career as a straight path, but as a series of crossings. Each one was a discovery, providing something I am excited to wake up and go out to search for answers.
Today, working from Switzerland, I'm synthesizing a new model for health and wealth, drawing on global strengths: the foundational human touch, the bold market vision, the meticulous system design, and the deep structural thinking. This unique blend converges on one urgent question: How can we transform prevention and healthy longevity from a complex possibility into a scalable, investable framework?
This journey has always pointed toward one destination: making longevity the next great asset class.